AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Recruiting
Observational Study
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Pancreatic Intraepithelial Neoplasias
Intraductal Papillary Mucinous Neoplasm
Mucinous Cystic Neoplasm
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 5,000 (estimated)
- Sponsor
- Changhai Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in \>80% of cases). This prospective, observational, multi-center study will evaluate the performance of an AI-powered opportunistic screening system utilizing non-contrast computed tomography (NCCT) acquired during routine…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
1\. Individuals undergoing routine non-contrast chest and/or abdominal CT scans for non-pancreatic indications.
Exclusion Criteria
1. History of pancreatic cancer;
2. History of thoracic or abdominal surgery;
3. Acute pancreatitis within 6 months;
4. Patients referred for evalu…
Contacts